Patents by Inventor Mark P. Ridgill

Mark P. Ridgill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonaminoquinoline hepcidin antagonists
    Patent number: 9102688
    Abstract: The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 11, 2015
    Assignee: Vifor (International) AG
    Inventors: Wilm Buhr, Susanna Burckhardt, Franz Dürrenberger, Felix Funk, Peter O. Geisser, Vincent A. Corden, Stephen M. Courtney, Graham Dawson, Tara Davenport, Mark Slack, Mark P. Ridgill, Christopher J. Yarnold, Susan Boyce, Albertus A. Ellenbroek
  • Novel Sulfonaminoquinoline Hepcidin Antagonists
    Publication number: 20140364424
    Abstract: The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 11, 2014
    Inventors: Wilm Buhr, Susanna Burckhardt, Franz Dürrenberger, Felix Funk, Peter O. Geisser, Vincent A. Corden, Stephen M. Courtney, Graham Dawson, Tara Davenport, Mark Slack, Mark P. Ridgill, Christopher J. Yarnold, Susan Boyce, Albertus A. Ellenbroek
  • Novel Ethanediamone Hepcidine Antagonists
    Publication number: 20120214798
    Abstract: The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
    Type: Application
    Filed: September 6, 2010
    Publication date: August 23, 2012
    Applicant: VIFOR (INTERNATIONAL) AG
    Inventors: Franz Dürrenberger, Susanna Burckhardt, Wilm Buhr, Peter O. Geisser, Felix Funk, Vincent A. Corden, Stephen M. Courtney, Tara Davenport, Stefan Jaeger, Mark P. Ridgill, Mark Slack, Christopher J. Yarnold, Wei Tsung Yau
  • Novel Sulfonaminoquinoline Hepcidin Antagonists
    Publication number: 20120214803
    Abstract: The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 23, 2012
    Applicant: VIFOR (INTERNATIONAL) AG
    Inventors: Wilm Buhr, Susanna Burckhardt, Franz Dürrenberger, Felix Funk, Peter O. Geisser, Vincent A. Corden, Stephen M. Courtney, Graham Dawson, Tara Davenport, Mark Slack, Mark P. Ridgill, Chrostopher J. Yarnold, Susan Boyce, Albertus A. Ellenbroek
  • Novel Pyrimidine- And Triazine-Hepcidine Antagonists
    Publication number: 20120202806
    Abstract: The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
    Type: Application
    Filed: August 31, 2010
    Publication date: August 9, 2012
    Applicant: VIFOR (INTERNATIONAL) AG
    Inventors: Franz Dürrenberger, Susanna Burckhardt, Peter O. Geisser, Wilm Buhr, Felix Funk, Julia M. Bainbridge, Vincent A. Corden, Stephen M. Courtney, Tara Davenport, Stefan Jaeger, Mark P. Ridgill, Mark Slack, Christopher J. Yarnold, Wei Tsung Yau
  • Pyrrolo-pyridine derivatives
    Patent number: 5622950
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 22, 1997
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
  • Pyrrolo-pyridine derivatives
    Patent number: 5576319
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: August 26, 1994
    Date of Patent: November 19, 1996
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
  • Pyrrolo-pyridine derivatives
    Patent number: 5432177
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: July 11, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill